Pegasys® (peginterferon alfa-2a) – Expanded indication
October 13, 2017 – The FDA approved Hoffman-LaRoche’s Pegasys (peginterferon alfa-2a), for the treatment of HBeAg-positive chronic hepatitis B (CHB) in non-cirrhotic pediatric patients 3 years of age and older with evidence of viral replication and elevations in serum alanine aminotransferase.
Top